Cargando…
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
Several molecular subtypes of cancer are highly dependent on splicing for cell survival. There is a general interest in the therapeutic targeting of splicing by small molecules. E7107, a first-in-class spliceosome inhibitor, showed strong growth inhibitory activities against a large variety of human...
Autores principales: | Aptullahoglu, Erhan, Ciardullo, Carmela, Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916657/ https://www.ncbi.nlm.nih.gov/pubmed/36768733 http://dx.doi.org/10.3390/ijms24032410 |
Ejemplares similares
-
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells
por: Ciardullo, Carmela, et al.
Publicado: (2019) -
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia
por: Aptullahoglu, Erhan, et al.
Publicado: (2023) -
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018) -
Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis
por: Zheng, Tongsen, et al.
Publicado: (2013) -
p53 as a biomarker and potential target in gastrointestinal stromal tumors
por: Wu, Chiao-En, et al.
Publicado: (2022)